Can Pembrolizumab be used in combination?

Pembrolizumab can be used in combination. Approved by the FDA, pembrolizumab can be used in combination with pemetrexed and platinum-based chemotherapy, and is suitable for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic tumor abnormalities.

Pembrolizumab may also be used in combination with platinum and a fluorouracil (FU) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. It may also be used with ennozumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-based chemotherapy. It may also be used with platinum- and fluoropyrimidine-based chemotherapy. It can also be used in combination with chemotherapy, with or without bevacizumab, in patients with squamous cell histology tumors determined by FDA-approved trials to express PD-L1 (CPS ≥ 10).

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.